Upregulation of SETD1B was found to activate iNOS expression in tumor-induced myeloid-derived suppressor cells, which could provide a foundation for establishing an effective approach for improving the efficacy of cancer immunotherapy by targeting SETD1B [182]. Here, SETD1B is linked to neoplasm.